title: AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
abstract: OBJECTIVE
  The present study aimed to compare the outcome of secondary cytoreductive surgery retrospectively in patients with positive and negative Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score that were operated on at the Department of Gynecology, Charité Comprehensive Cancer Center, Medical University, between 2006 and 2013.
  
  
  METHODS
  A total of 209 consecutive patients presenting a first recurrence of epithelial ovarian cancer were enrolled: 139 patients had a positive AGO score, and 70 patients had at least one negative criterion of the AGO score. All patients underwent secondary cytoreductive surgery and data were evaluated retrospectively.
  
  
  RESULTS
  Total macroscopic tumor resection was obtained during secondary cytoreductive surgery in 127 patients (61%), 93 (67%) in the AGO-positive group and 34 (48.5%) in the AGO-negative group. Overall (OS) and progression-free survival (PFS) were identical in both groups of patients when secondary cytoreductive surgery succeeded in achieving complete tumor resection. PFS was 22 months in AGO-positive patients who were tumor-free after secondary cytoreductive surgery and 21 months in AGO-negative patients with complete resection after secondary cytoreductive surgery. There were no significant differences in morbidity and mortality rates for both groups.
  
  
  CONCLUSIONS
  AGO score is a useful predictor for operability in patients with a first recurrence of ovarian cancer. Patients with negative scores may still have a 50% chance of achieving optimal tumor resection after secondary cytoreductive surgery. This will be a pivotal factor when counseling patients with recurrent disease regarding further management options.
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany Mustafa-Zelal.Muallem@charite.de.
authors.forename: Mustafa Zelal
authors.initials: MZ
authors.lastname: Muallem
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany Ovarian Cancer Tumor Bank, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Khayal
authors.initials: K
authors.lastname: Gasimli
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Rolf
authors.initials: R
authors.lastname: Richter
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Jumana
authors.initials: J
authors.lastname: Almuheimid
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Sara
authors.initials: S
authors.lastname: Nasser
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany Ovarian Cancer Tumor Bank, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Elena Ioana
authors.initials: EI
authors.lastname: Braicu
authors.affiliation: Department of Gynecology, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D065426:Cytoreduction Surgical Procedures; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*
keywords: AGO-score; ovarian cancer; secondary cytoredustive surgery